JP2024536132A5 - - Google Patents
Info
- Publication number
- JP2024536132A5 JP2024536132A5 JP2024519267A JP2024519267A JP2024536132A5 JP 2024536132 A5 JP2024536132 A5 JP 2024536132A5 JP 2024519267 A JP2024519267 A JP 2024519267A JP 2024519267 A JP2024519267 A JP 2024519267A JP 2024536132 A5 JP2024536132 A5 JP 2024536132A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- disease
- related protein
- polyq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21199761.4 | 2021-09-29 | ||
| EP21199761 | 2021-09-29 | ||
| PCT/EP2022/076748 WO2023052317A1 (en) | 2021-09-29 | 2022-09-27 | Rna editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536132A JP2024536132A (ja) | 2024-10-04 |
| JP2024536132A5 true JP2024536132A5 (https=) | 2025-10-02 |
Family
ID=78179173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519267A Pending JP2024536132A (ja) | 2021-09-29 | 2022-09-27 | Ｒｎａ編集方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240336919A1 (https=) |
| EP (1) | EP4408999A1 (https=) |
| JP (1) | JP2024536132A (https=) |
| CN (1) | CN118019848A (https=) |
| AR (1) | AR127158A1 (https=) |
| TW (1) | TW202329983A (https=) |
| WO (1) | WO2023052317A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202405143D0 (en) * | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009099326A1 (en) * | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US10202599B2 (en) | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2013033223A1 (en) * | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US20150315595A1 (en) | 2012-03-12 | 2015-11-05 | Santaris Pharma A/S | Compositions and Methods for Modulation of ATXN3 Expression |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| LT2841578T (lt) * | 2012-04-23 | 2017-09-25 | Biomarin Technologies B.V. | Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui |
| US10435430B2 (en) | 2013-07-31 | 2019-10-08 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| EP3234134B1 (en) | 2014-12-17 | 2020-05-27 | ProQR Therapeutics II B.V. | Targeted rna editing |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| WO2019158475A1 (en) | 2018-02-14 | 2019-08-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for rna editing |
| US20200385713A1 (en) * | 2019-01-22 | 2020-12-10 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
-
2022
- 2022-09-27 JP JP2024519267A patent/JP2024536132A/ja active Pending
- 2022-09-27 CN CN202280064982.3A patent/CN118019848A/zh active Pending
- 2022-09-27 EP EP22797687.5A patent/EP4408999A1/en active Pending
- 2022-09-27 WO PCT/EP2022/076748 patent/WO2023052317A1/en not_active Ceased
- 2022-09-27 AR ARP220102593A patent/AR127158A1/es unknown
- 2022-09-28 TW TW111136781A patent/TW202329983A/zh unknown
-
2024
- 2024-03-27 US US18/618,604 patent/US20240336919A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5545729A (en) | Stabilized ribozyme analogs | |
| DE69514351T2 (de) | Verzweigte Oligonukleotide als pathogenhemmende Mittel | |
| JP7197463B2 (ja) | Ｓｍｎ２の調節のための化合物及び方法 | |
| JP2021510511A5 (https=) | ||
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| JP2024536132A5 (https=) | ||
| JP2018529732A5 (https=) | ||
| JP2019525918A5 (https=) | ||
| JP7446443B2 (ja) | Ｓｍｎ２を調節するための化合物及び方法 | |
| JP2021505129A5 (https=) | ||
| JP2022527105A5 (https=) | ||
| JP2024112834A5 (https=) | ||
| JP7211933B2 (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| TWI791868B (zh) | 調節rtel1表現之寡核苷酸 | |
| JP2022550979A5 (https=) | ||
| JP2021510512A5 (https=) | ||
| JP2024522272A5 (https=) | ||
| TW202329983A (zh) | Ｒｎａ編輯 | |
| JP2024522147A5 (https=) | ||
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2021513851A5 (https=) | ||
| WO2024046937A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2025508959A5 (https=) | ||
| Peyrottes et al. | Dramatic effect of the anomeric configuration on the thermal stability of duplex formed between novel dodecathymidine phosphoramidate (PNH2) and complementary DNA and RNA strands | |
| JP2024519204A (ja) | 複数の標的を介して疼痛を処置するための治療組成物 |